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Abstract
Background. Lower-limb edema is recognized as an
untoward side effect of intrathecal opioid therapy.
Cellulitis, an acute, spreading pyogenic inflamma-
tion of the dermis and subcutaneous tissue, predis-
posed by persistent leg edema, can become
problematic in patients on intraspinal opioid infu-
sion therapy.
Objective. To present a case of recurrent cellulitis in
an elderly lady with persistent leg edema associated
with intrathecal morphine/hydromorphone infusion
therapy.
Case Report. Sixty-one-year-old woman with intrac-
table chronic low back pain and bilateral leg pain
treated with an intrathecal infusion of morphine up
to 5 mg/day over 3 months with satisfactory pain
control developed progressive lower extremity
edema, complicated by recurrent cellulitis, requiring
repeated hospitalization and intravenous antibiotic
treatment. Switching to intrathecal hydromorphone
helped minimally. Intrathecal baclofen and clonidine
infusion resulted in complete resolution of leg
edema and pain relief over the following 12 months.
Conclusion. Intrathecal Baclofen and Clonidine
may be used as alternatives to provide spinally
mediated antinociception when intraspinal opioid
fails due to pharmacological side effects such as
persistent edema.
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Spinal analgesia, mediated by opioid receptors, requires
only a fraction of the opioid dose needed systemically. By
infusing a small amount of opioid into the cerebrospinal fluid
in close proximity to the receptor sites in the spinal cord,
profound analgesia may be achieved. Intraspinal drug
delivery of opioid(s), via an implanted pump and catheter, is
increasingly used in a subset of patients with intractable,
chronic pain who have failed to respond to conventional
treatment, or could not tolerate systemic opioid due to side
effects [1–5]. Prior to the permanent pump implantation, an
intraspinal analgesic infusion trial is usually done, to docu-
ment efficacy of IDD therapy, and to make sure that the
patient is without intolerable side effects. Generally, 50%
pain reduction, or patient’s subjective report of “significant
pain relief” during the trial, or demonstrable improved func-
tional level during the trial, constitutes a positive trial [1].
Morphine, the only FDA-approved opioid for intrathecal
administration, is considered effective, inexpensive, and
well tolerated by majority of patients, yet, clinically relevant
side effects associated with long-term intrathecal morphine
administration have become evident [6,7]. These include
pruritis, nausea, vomiting, constipation, edema, sexual
dysfunction, urinary retention, and respiratory depression
[6,7]. Leg edema associated with intrathecal opioid therapy
has been increasingly recognized as a problematic com-
plication [6,8,9].
Cellulitis is an acute bacterial infection of the dermis and
subcutaneous tissue that is associated with inflammation
[10,11]. We are reporting this case of recurrent cellulitis
because it is a rare occurrence and can lead to severe
morbidity.




A 61-year-old woman with intractable chronic low back
pain and bilateral leg pain, due to degenerative disc
disease, failed back surgery syndrome, and lumbar
radiculopathy, was referred to our clinic for intraspinal drug
delivery (IDD) therapy, after failing to respond to multidis-
ciplinary pain treatment. Following a satisfactory epidural
morphine infusion trial, she underwent placement of per-
manent intrathecal infusion pump. The intrathecal catheter
was introduced at left paramedian L2-L3 under fluoro-
scopic guidance, with catheter tip located at T12. Satis-
factory intrathecal catheter placement was confirmed by
observing positive cerebrospinal fluid (CSF) flow and intra-
operative myelogram. The intrathecal infusion was initially
started with preservative free morphine at 1 mg/day. Over
the following 3 months, the dosage was gradually titrated
up to 5 mg/day with satisfactory pain control, 2–3/10 on
visual analog pain scale (VAS) of 0–10. However, she
developed progressive lower extremity edema and was
fitted for compression stockings and prescribed diuretics
(furosemide 20 mg bid) with limited success. Subse-
quently, after dose reduction to 3 mg/day, her leg edema
improved, so that although she continued to wear com-
pression stockings, she was able to discontinue the
diuretic. Over the following 2 months, after her back and
leg pain worsened to 6–7/10 on VAS, the intrathecal mor-
phine dose was titrated to 5 mg/day. However, leg edema
recurred, which was resistant to furosemide.
Meanwhile, the patient developed sudden onset of warm,
tender erythema of bilateral lower extremities with a fever
of 101.8°F. Urinanalysis, urine culture, and chest X-ray
were unremarkable, and bilateral lower extremity Doppler
study was negative for any blood clots.
She was admitted to the hospital with a working diagnosis
of severe cellulitis for intravenous (IV) antibiotic treatment,
where she was treated for 3 days with aggressive IV
furosemide, oral hydrochlorothiazide (HCTZ), compres-
sion stockings, and IV cefazolin, with only slight improve-
ment of leg edema but improvement of leg cellulitis. She
was discharged home on oral Keflex for a total of 2 weeks
of antibiotic treatment (IV + PO). Serial blood cultures after
hospitalization came back negative for any bacterial
growth, and her low back and leg pain remained “toler-
able” on intrathecal morphine 5 mg/day. Two months later,
her cellulitis recurred, requiring another hospitalization for
4 days of IV antibiotic treatment, followed by outpatient
oral antibiotics 10 days in conjunction with both furo-
semide and HCTZ.
Subsequent to recurrent edema and leg cellulitis on intra-
thecal morphine, she was switched to intrathecal hydro-
morphone, starting at 1 mg/day and titrated to 1.8 mg/day.
Her edema lessened, and her pain remained under satis-
factory control, 2–3/10 on VAS, and she was able to
discontinuecompression stockings and diuretics. Two
months later, however, she experienced worsening low
back and leg pain, 6–7/10 on VAS, so the intrathecal
hydromorphone was increased to 2.6 mg/day, with recur-
rence of leg edema followed by severe bilateral leg cellulitis,
again requiring hospital admission for intravenous antibiotic
followed by oral antibiotics. The cellulitis resolved following
antibiotics treatment, but the leg edema persisted.
After struggling with recurrent severe cellulitis and persis-
tent leg edema, it was finally decided to switch her intra-
thecal regimen to clonidine 33 mcg/day and baclofen
67 mcg/da,y resulting in complete resolution of edema,
enabling her to discontinue both compression stockings
and diuretics. Her pain remained “tolerable” around
2–4/10 on VAS over the following 12 months, requiring
only slight dosage elevation of intrathecal clonidine
(67 mcg/day) and baclofen (100 mcg/day). She has had
no recurrent leg edema or cellulitis.
Discussion
Cellulitis is an acute bacterial infection of the dermis and
subcutaneous tissue that is clinically associated with clini-
cal inflammation [10,11]. The area, usually on the leg, is
warm, tender, erythematous, and swollen. It lacks sharp
demarcation from uninvolved skin. The diagnosis of cellu-
litis is based on the clinical ground, i.e., the morphologic
features of the lesion and clinical settings [12]. Strepto-
cocci (Group A, B, G) and Staphylococcus aureus are the
most frequently isolated pathogens [12]. Bacteremia is
uncommon in cellulitis. Previous studies showed that out
of 272 patients, initial blood culture was positive only in
about 4% [13,14], indicating blood culture not being cost-
effective for most patients with cellulitis. Empirical antibi-
otics with intravenous cephalosporin, followed by oral
cephalosporin for total of 7–14 days are usually employed
for moderate or severe cellulitis [12].
Edema predisposes patients to cellulitis [15]. Persistent
edema after recovery from cellulitis predisposes patient to
recurrent cellulitis [15]. The precise pathophysiological and
immunological responses in this disposition to cellulitis
remain to be poorly understood [16]. Leg edema, associ-
ated with intraspinal opioid therapy, has been increasingly
recognized along with the increased utilization of this treat-
ment modality for intractable, chronic pain [6,8,9]. It has
been widely accepted that the mechanism of spinally
opioid-induced edema to be the cephalad migration of
morphine in CSF, and subsequent interaction with opioid
receptors in the posterior pituitary gland, stimulating vaso-
pressin release [6,7].
Recently, we reported a case of an otherwise healthy
elderly female with failed back surgery syndrome who
developed severe peripheral edema while on continuous
epidural morphine infusion [17]. We also noticed the early
research by Huidobro-Toro et al. [18] and Denesh et al.
[19]. Huidobro et al. [18], who observed striking difference
in urine electrolytes in rats following intraventricular injec-
tion of antidiuretic hormone and opioids, respectively; the
former being oliguria with high concentration of Na+ and
K+, while the latter being very low concentration of urine
electrolytes, suggesting spinal opioids selectively activate
central opioid receptors to produce changes in urine for-
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mation and composition. Denesh et al. [19] demonstrated
that centrally administered morphine in conscious rats
enhanced renal tubular sodium reabsorption, by opioid
receptor-dependent mechanism. So, our speculation is
that both centrally mediated renal effect (through alteration
of urine electrolyte composition) and centrally mediated
vasopressin release may be the underlying mechanism of
spinal opioid-induced edema. In our patient, we believed
that the recurrent cellulitis was predisposed by lower
extremity edema. When she repeatedly developed edema
with cellulitis while on intrathecal morphine, we decided to
switch her intrathecal opioid to hydromorphone.
Hydromorphone, a semisynthetic derivative of morphine,
is considered to be equianalgesic at a ratio of 1:5–1:8
[20,21]. It is more lipophilic than morphine, therefore pen-
etrating the spinal cord more rapidly, leaves less time for it
to ascend cephalad in CSF [20,22], and is expected to
have less side effects due to rostral spread of the drug in
comparison with morphine. Hydromorphone has been
increasingly used off-label over the past a few years for
long-term intrathecal therapy [23]. Deer et al. recently
published the most up-to-date expert panel recommen-
dations on intrathecal drug selection—the “Polyanalgesic
Algorithm” [23]. It calls for the selection of intrathecal
analgesics for long-term intrathecal infusion in the
order from line 1 to line 6 (line 1 agents include
morphine, hydromorphone, and ziconotide; line 2 agents
include fentanyl, morphine/hydromorphone + ziconotide,
morphine/hydromorphone + bupivacaine/Clonidine; line 3
agents include Clonidine, morphine/hydromorphone/
fentanyl, bupivacaine +/Clonidine + ziconotide; line 4
agents include sufetanil, sufetanyl + bupivacaine
+/Clonidine + ziconotide; line 5 agents include ropiv-
ocaine, buprenophine, midzolam, meperidine, ketorolac;
line 6 agents include other experimtental drugs) [23]. The
switch of intrathecal morphine to hydromorphone did not
deviate from the “polyanalgesic algorithm,” as hydromor-
phone is considered a line 1 agent, although the rationale
for this switch was due to the edema caused by intra-
thecal morphine rather than inadequate analgesia.
Her pattern of initial improvement of peripheral edema,
followed by recurrence of edema with intrathecal hydro-
morphone, was previously observed by Anderson et al.
[9], who reported their findings in a retrospective review of
37 patients with chronic nonmalignant pain managed with
intrathecal hydromorphone. However, there was no cellu-
litis reported, and to this day, there have been no other
reported cases of cellulitis associated with intrathecal
opioid infusion therapy. It is quite likely that this is under-
reported, considering the incidence of peripheral edema
due to intraspinal opioid being from 6.1% [24] to 21.7%
[25].
Although Ziconotide is listed as a Line 1 agents, we did
not use it in our patient for the following reasons: 1)
ziconotide can only be used with programmable infusion
pump such as Medtronic SynchroMed (Prialt package
insert). Ziconotide has a very narrow therapeutic window
that requires starting low at 0.5 mcg/day, gradually
increasing dosage at no more than 0.5 mcg/day, until
therapeutic dose is achieved [26]. This highly meticulous
titration process mandates a programmable pump such
as Medtronic SynchroMed infusion pump, not the
constant-flow rate, nonprogrammable Codman pump in
our patient, which we use because it is less expensive and
lasts longer [28]. The only way to change drug infusion
dose with the nonprogrammable, constant flow rate
pump, is by replacing pump medication with different drug
concentration during pump refill. 2) Ziconotide is very
expensive and has high incidence of side effects, including
psychiatric, neurological, cardiovascular, and gastrointes-
tinal symptoms [27].
The main reason that we routinely implant non-
programmable Codman constant-flow pumps is that they
are much less expensive than the Medtronic program-
mable pump [28]. This is especially true when one con-
siders the effect that programmable pumps require
multiple replacement surgeries about every 5 years due
to limited battery lifespan [29]. Staats et al. [28] recently
conducted a retrospective study in 101 patients who
received programmable infusion pumps for management
of nonmalignant low back pain, and found out that
almost all patients stayed on constant-flow treatment
within the normal battery lifespan. They further suggested
that programmable infusion pumps be replaced by
constant-flow pumps at the first pump replacement
surgery.
Although bupivacaine is listed as adjunct agent in line 2, 3,
and 4, it was advocated to be used, only in conjunction
with opioids (morphine/hydromorphone or fentanyl) rather
than to be used alone [23]. We were also concerned
about the possibility that intrathecal bupivacaine could
worsen leg edema by interrupting the sympathetic
outflow, causing venous pooling, which was described by
Bridenbaugh et al. [30]. Since we speculated that intrath-
ecal opioids (morphine or hydromorphone) were respon-
sible for causing recurrent leg edema, combining opioid(s)
with bupivacaine for intrathecal infusion, obviously, would
not solve the problem of leg edema. In our patient, we
believed that the spinal opioid-induced edema involves
both centrally mediated renal function (resulting in urine
electrolyte composition change) and centrally opioid
receptor-mediated opioid interaction with posterior pitu-
itary (leading to vasopressin release).
Unfortunately, agents in line 2, 3, and 4 all involve opioids.
Faced with these limitations, in view of multiple recurrent
lower extremity edema and recurrent cellulitis in our
patient while on intrathecal clonidine, is a centrally acting
alpha2-adrenoreceptor agonist believed to act at the
alpha2 adrenoreceptors in the dorsal horn to modulate
afferent nociceptive input by pre- and postsynaptic
mechanism [31–33]. Clonidine has been shown to be
effective in treating neuropathic pain, including complex
regional pain syndrome (CRPS) [34–36]. Hassenbusch
et al. demonstrated the tolerability and efficacy of intrath-
ecal Clonidine in the treatment of chronic pain through a
phase I/II study [37].
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Baclofen, a gamma-amino-butyric acid (GABA B) agonist,
has been widely used intrathecally in the management of
spasticity due to upper motor neuron syndromes, such as
spinal cord injury, multiple scleroisis, traumatic brain injury,
etc. [38]. The antispastic properties of baclofen are medi-
ated by the suppression of release of excitatory neu-
rotransmitters and inhibition of excitatory afferent
terminals involved in monosynaptic and polysynaptic
reflex activity at the spinal cord level [39,40]. Only recently
have the antinociceptive effects of intrathecal baclofen,
independent of motor blockade, been suggested [41,42].
Lastly, we would like to emphasize the importance of
adhering to the “polyanalgesic algorithm” when utilizing
intrathecal analgesic drug therapy for pain management,
as complications do occur, especially with intrathecal
baclofen, as serious withdrawal symptoms have been
reported [43,44].
Conclusion
Peripheral edema becomes increasingly recognized as a
potential side effect of intraspinal opioid infusion therapy.
Persistent leg edema predisposes patients to recurrent
cellulitis. Opioid dosage reduction or switching to nono-
pioid analgesics may be required to resolve the edema
induced by intrathecal opioid, and to prevent the devel-
opment of associated cellulitis. Intrathecal baclofen and
clonidine may be used as alternative, under certain cir-
cumstances, to provide spinally mediated antinociception,
when intraspinal opioid fails because of intolerable phar-
macological side effects.
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